at Investor's Business Daily (Mon, 6:42PM)
Mylan Laboratories (MYL -0.9%) has the opportunity to "create" earnings if a shortfall exists after it bought intellectual knowledge from Pfizer, according to forensic accounting expert Howard Schilit. The key is a $348M contingent consideration liability the company carries for possible milestone payments, royalties, and profit sharing on the deal that can be legally adjusted in any given quarter to reduce expenses for the period.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Nasdaq.com (Jan 21, 2015)
at Zacks.com (Jan 12, 2015)
at Zacks.com (Jan 9, 2015)
at Zacks.com (Jan 7, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs